Age (HR, 1.034; 95% CI, 1.021–1.047; P < 0.001), stage (III vs I: HR, 3.026; 95% CI, 1.706–5.368; P < 0.001; IV vs I: HR, 13.042; 95% CI, 6.430–26.453; P < 0.001) and IHC-based subtypes (HR-/HER2- vs HR + /HER2-,1.811; 95% CI, 1.125–2.914; P = 0.015) were also prognostic factors for BC. This evidence concerns the gene ERBB2 and breast cancer.